The main objective of this study is establish the performance of miR371 in management of testicular cancer
The main objective of the study is to asses the sensitivity and specificity of microRNA-371a-5p (miR371) in detection of viable testicular germ tumour cells. To assess the utility of miR371 at orchiectomy, during treatment and surveillance and in early detection of recurrence.
Study Type
OBSERVATIONAL
Enrollment
350
Blood collection. Blood samples will be collected at diagnosis, during surveillance, during treatment and every 3-6 months
Haukeland University Hospital
Bergen, Norway
RECRUITINGHaugesund Hospital
Haugesund, Norway
RECRUITINGOslo University Hospital
Oslo, Norway
miR371 as a biomarker in testicular germ cell cancer at orchiectomy
To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at diagnosis
Time frame: 5 years
miR371 as a biomarker in testicular germ cell cancer at RPLND
To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at RPLND
Time frame: 5 years
miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment
To estimate the performance of miR371 in monitoring of treatment efficiency (chemotherapy)
Time frame: 5 years
miR371 as a biomarker in testicular germ cell cancer and detection of recurrence
To estimate the performance of miR371 in (early) detection of recurrence
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University Hospital of North Norway
Tromsø, Norway
RECRUITINGSahlgrenska University Hospital
Gothenburg, Sweden
NOT_YET_RECRUITINGKarolinska University Hospital
Stockholm, Sweden
RECRUITING